新冠疫苗現重大進展 港股航空、影視、旅遊股全線高開
格隆匯11月10日丨疫苗方面傳來重磅利好,輝瑞和BioNTech宣佈,他們聯合研製的新冠候選疫苗在第3期臨牀試驗研究的中期分析中取得了重大進展,疫苗的預防效力高達90%。兩家公司預估到今年年底,能夠生產、供應全球多達5000萬劑疫苗,2021年底則將增加至13億劑。此前受疫情影響的港股市場航空、影視和旅遊股今日全線高開。航空股中,國泰航空高開14.95%,東方航空高開10.37%,中國國航高開11.84%,南方航空高開8.97%;影視股中,IMAX中國高開4.87%,貓眼娛樂高開6.79%,阿里影業高開2.75%;旅遊股中,雲頂香港漲14%,縱橫遊控股漲13.73%,同程藝龍漲8.82%,香港中旅漲8.49%,太陽城集團漲7.46%。



Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.